IDIS and Ogilvy to promote named patient programme
April 28, 2009Medical Communications, Sales and Marketing IDIS, Ogilvy
Specialist medicines supplies company IDIS has hired a leading PR agency to help promote its business across Europe. Ogilvy Healthworld …
The changing face of Continuing Medical Education in Europe
April 28, 2009Medical Communications, Sales and Marketing Continuing medical education, Europe
There is currently no unified approach to delivering Continuing Medical Education (CME) in Europe, and the provision of CME is …
Patheon takeover stymied by regulators
April 28, 2009Manufacturing and Production Patheon
A hostile takeover bid for Canadian contract manufacturer Patheon by private equity firm JLL Partners has been blocked by the …
Pfizer taps UCL for stem cell expertise
April 28, 2009Research and Development Pfizer, UCL, ophthalmology, regenerative medicine
Pfizer will work with researchers from University College London in the UK to try to develop stem cell-based therapies for …
AZ’s Iressa to make comeback
April 28, 2009Research and Development, Sales and Marketing AZ, Iressa
AstraZeneca's Iressa is set to make a comeback after a European committee recommended its use for a sub-group of lung …
Questions and answers
April 27, 2009Medical Communications Pfizer, Q&A, communications
As a young child, I am reliably informed that "why" was my favourite word for an extended period. While that …
Mixed news for Biogen Idec on Tysabri
April 27, 2009Manufacturing and Production Biogen
Biogen Idec has won approval for a new high-titre manufacturing process for its multiple sclerosis product Tysabri (natalizumab) which should …
GSK and Pfizer joint venture more than a defensive move
April 27, 2009Research and Development, Sales and Marketing GSK, Pfizer
GSK and Pfizer have agreed to merge their respective HIV businesses, creating a single specialist entity with total pro-forma sales …
Strong prospects for Novartis cancer drug, say analysts
April 24, 2009Research and Development, Sales and Marketing Afinitor, Novartis
The FDA has approved Novartis's Afinitor for advanced renal cell carcinoma patients who have progressed after first-line Sutent or Nexavar …
GSK freezes prices in Germany as part of PR trail
April 24, 2009Sales and Marketing GSK, Germany
GlaxoSmithKline has announced a price freeze on its drugs and vaccines in Germany for 2009. The freeze applies to drugs …
Merck Serono launches Kuvan in Europe
April 24, 2009Sales and Marketing Kuvan, Merck Serono, PKU
Kuvan, the first treatment for two rare neurological disorders, has been launched in the UK, France and Germany.Merck Serono’s drug …
Pharma welcomes UK taxation pledge
April 23, 2009ABPI
The UK government budget delivered in the gloom of the recession has provided good news for the industry, according to …
Sanofi-Aventis commits 100 million euros to Chinese expansion
April 23, 2009Research and Development Asia, China, Sanofi-Aventis
France's Sanofi-Aventis is planning a major capital investment programme in Beijing in a bid to bolster its position in the …
NICE approves Bayer’s Xarelto
April 23, 2009Research and Development Bayer, NICE, Xarelto
NICE has approved Bayer's anti-clotting treatment Xarelto, bringing it into line with Boehringer Ingelheim's rival Pradaxa. Xarelto (rivaroxaban) was assessed …
Pharma-NHS joint working
April 22, 2009Research and Development, Sales and Marketing ABPI, doctors, industry relations
An underlying principle for joint working between the NHS and the pharmaceutical industry is that it brings benefits to patients. …
GSK launches Alli in Europe
April 22, 2009Sales and Marketing Alli, Europe, GSK
GSK has launched Alli, making it the first clinically proven over-the-counter weight loss aid to be available in pharmacies across …
Deal brings single ASEAN pharma market closer
April 22, 2009Manufacturing and Production Asia
An accord signed by economic ministers of the Association of Southeast Asian Nations, aimed at bringing manufacturing standards into line, …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
